Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Rush University Medical Center, Chicago, IL, USA.
J Parkinsons Dis. 2014;4(4):585-9. doi: 10.3233/JPD-140385.
Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.
认知障碍是帕金森病（PD）的常见症状，但其严重程度和具体表现因患者而异。最初的认知缺陷，包括轻度认知障碍（PD-MCI），可能保持稳定，或者在许多情况下，可能在不同的时间段内进展为帕金森病痴呆（PDD）。由于目前尚无针对轻度认知障碍的治疗方法，因此有机会在该领域确定治疗开发的途径。由于缺乏针对 PD-MCI 的治疗方法的明确批准途径，制药公司不太可能追求这一适应症。为了向前推进并改善 PD 患者的生活质量，该领域必须就 PD-MCI 的定义、衡量认知衰退的最佳工具以及未来临床试验的策略达成共识。
